Irbesartan

Hoʻokahi āpau antihypertensive, kahi ʻano hoʻokalakupua kōneʻawaʻawa e hiki ke hoʻokūkū i ka angiotensin II (type AT1). Hoʻopau i ka hopena vasoconstrictor o ka angiotensin II a hōʻemi i ka hoʻomohala ʻana o ka aldoster i ka plasma koko. ʻAʻole ke keʻokeʻo i ka kinase II - he enzyme e hoʻopau ai i ka bradykinin. Hoʻemi i ka OPSS, hoʻemi i ka ukana, hoʻemi i ke kahe mau o ke koko a me ka hoʻokele ʻana i ka kaʻe pulmonary. Hoʻohālikelike ka hopena kūpono loa i nā hola 3-6 ma hope o hoʻokahi pākēneka. Ke hoʻomau nei ka hopena antihypertensive no nā hola 24. Loaʻa ʻia kahi hopena neʻe paʻa ma hope o 1-2 mau wiki o ka hoʻohana ʻana i ka irbesartan. Ma hope o ka hoʻopaʻa ʻana i ka hoʻokomo o ke kahe koko e hoʻi mālie nei i kona pae mua. ʻAʻole hopena ʻo Irbesartan i ka hoʻoneʻe ʻana o TG, ka nui o ka cholesterol, ka glucose, ka waikū uric i loko o ke koko koko a i ʻole ka hoʻōki ʻana o ka uric acid i ka urine.
Ma hope o ka lawelawe waha, ua hoʻopili maikaʻi ʻia mai ka digestive tract. ʻO ka pae kiʻekiʻe loa o ka irbesartan i loko o ke koko koko a hōʻea ma hope o 1.5-2 mau hola ma hope o ka nānā ʻana. Bioavailability 60-80%. ʻO ka ʻai pinepine ʻana ʻaʻole pili i ka bioavailability. ʻO ka pilina o Protein ma kahi o 90%. Hoʻomiliʻia ka Irbesartan i ka ate ma muli o ka conjugation me ka hoʻokumuʻana o glucuronide a ma muli o ka hopena o ka maʻi oxidation. ʻO ka metabolite nui ka irbesartan glucuronide (ma kahi o 6%). ʻO ka pau ʻana o ka hapalua ola-he mau hola 11-15. I nā mea maʻi me ka puʻuwai a i ʻole a hana ʻole paha i ka hana lā, ʻaʻole i loli nui ka nui o nā pharmacokinetic o irbesartan.

ʻO ka hoʻohanaʻana i ka lāʻau lapaʻau Irbesartan

ʻO ka dosis mua ka 150 mg hoʻokahi i ka lā, a laila hiki ke hoʻonui ʻia ke ʻano iā 300 mg hoʻokahi i ka lā, ua lawe ʻia me ka meaʻai a i ʻole ka ʻōpū ʻole. Hoʻomaopopo ʻia e lawe i kēlā me kēia lā i ka like me ka manawa like. Inā haʻalele ʻoe i kahi pona, ʻaʻole e pāpālua ʻia ka nui o ka lā ma mua. Hoʻohui hui pū me nā irbesartan i hui pū me ka diuretics (hydrochlorothiazide) a i ʻole nā ​​lāʻau antihypertensive ʻokoʻa.

ʻO nā ʻōlelo kikoʻī kūikawā no ka hoʻohana ʻana i ka lāʻau Irbesartan

Hiki i ka diuretika kiʻekiʻe ma mua o irbesartan hiki ke alakaʻi i ka dehydration a hoʻonui i ka hiki o ka hypotension i ka hoʻomaka o ka mālama ʻana. Me ka wai nui o ka maʻi a i ʻole hyponatremia ma muli o ke ʻano diuretic intensive, he hale hyponatrium, ʻeha a ʻōlelo ʻole paha, a me nā mea e maʻi ana ma ka hemodialysis, e hoʻemi ʻia ka nui o nā irbesartan.
Inā pono, ʻo ka koho ʻana o ka ʻōpio i ka wā o ka ʻōpū e pono ai e hoʻoholo i ka hoʻopau ʻana o ka umauma. ʻAʻole paʻa i ka palekana a me ka hana o ka irbesartan i nā keiki.

Lapaʻau

Hōʻuluʻeha kiʻekiʻe a i ʻole ke ālai ʻia angiotensin II receptors (AT subtype₁) Hoʻopau i ka hopena vasoconstrictor o ka angiotensin II, e hoʻohaʻahaʻa i ka ʻaila o ka aldosterone i loko o ka plasma, e hōʻemi ana i ka OPSS, ma hope o ka puʻuwai, ka hopena o ke koko a me ke kaomi i ke kaomi pulmonary. ʻAʻole pili i ka kinase II (ACE), ka mea e hoʻopau ai i ka bradykinin a pili i ka hoʻokumu o ka angiotensin II. E hana lohi, ma hope o hoʻokahi pākahi, hoʻomohala ʻia ka hopena kiʻekiʻe ma hope o nā hola 3-6. E hoʻomau ka hopena antihypertensive no nā hola 24. I ka manawa pinepine e hoʻohana ai no 1-2 mau wiki, lilo ka hopena a hiki i ka lōʻihi ma hope o nā 4-6 mau pule.

ʻOi wikiwiki a piha loa mai ka pale ʻana i ke kaomi ʻai, ka kūʻokoʻa o ka lawoʻa ʻana he kūʻokoʻa ʻole ka kaʻai o ka meaʻai. Bioavailability - 60-80%, C_max hoʻoholo ʻia ma hope o nā hola 1.5-2. Aia kahi pilina linear ma waena o ke ʻano o ka irbesartan a me kona paʻa ʻana i ke koko (ma ke ʻano o ka nui o kēlā me ka 60000). Loaʻa ka pīpī plasma Equilibrium i loko o 3 mau lā ma hope o ka hoʻomaka ʻana o ka mālama ʻana. ʻO ka pilina ʻana o ka protein he 96%, ʻo ka helu hoʻoili he 53–93 L, ka huina Cl he 157-1176 ml / min, renal Cl he 3-3.5 ml / min. E hana ana i ka biotransformation ma ke kōpaʻa ma ka oxidation me ka komo ʻana o ka CYP2C 9 o ka isoenzyme CYP2C 9 o ka cytochrome P450 a ma hope ke kipi me ka hoʻokumu ʻana o nā metabolite hana ʻole, ʻo ia ka mea nui a ka irbesartan glucuronide (6%). T_1/2 - mau hola - 11-15. Kuhi ʻia e nā pūpū (20%, nona ka emi ma lalo o 2% i loli) a me ka puʻupaʻa.

ʻO ka hoʻokele ʻana i nā holoholona (nāhelehe, heluheluques) i nā kaʻe kiʻekiʻe (ʻoi aku ma mua o 500 mg / kg / lā) i ukali ʻia me ka hoʻomohala ʻana o nā loli degenerative i loko o ka lolo (interstitial nephritis, hoʻoulu tubular a / a peʻa paha i ka basophilic infiltration o nā pāhola renal, hoʻonui nui ʻana i ka waikika uric a me nā mea hana i loko o ka plasma) a me kahi kaila. pale ʻaihala. I nā poho ma mua o 90 mg / kg / lā (nā lālani) a me 110 mg / kg / lā (heluheluques) e hoʻolalelale ana i ka hypertrophy / hyperplasia o nā loko juxtaglomerular.

Ma lalo o nā kūlana o ka hoʻokele lōʻihi (2 mau makahiki) i nā holoholona hoʻokolohua ma nā pākuʻi ma mua o ka MPD, 3 mau manawa (nā kāne kāne), 3-5 mau manawa (male kāne a me nā wahine he nui) a me 21 mau manawa (nā kāne male) ʻaʻole i loaʻa ka hopena carcinogenic. I loko o ka noi ʻana o nā ʻano ʻē aʻe o nā pona, e ʻike ʻia ka hana mutagenic a me teratogenic.

Nā hopena hopena o ka waiwai Irbesartan

Mai ka pūnao a me ka hoʻonaninani naʻauao: ≥1% - pilikia nui, kuʻi, ʻeha, hopohopo / hoʻihoʻi.

Mai ka pūnaehana cardiovascular a me ke koko (hematopoiesis, hemostasis): ≥1% - tachycardia.

Mai ka papa hana hanu: ≥1% - nā maʻi ʻeha hanu o luna (maʻi, a me nā mea āpau), sinusopathy, sinusitis, pharyngitis, rhinitis, ʻōpala.

Mai ka hāliʻi ʻana o ka huina: ≥1% - ka maʻi pā, ka lua, ka luaʻi, ka hōʻailona dyspeptic, ka ʻōpū o ka ʻōpū.

Mai ka ʻōnaehana musculoskeletal: ≥1% - ka ʻeha o ka musculoskeletal (me ka komo ʻana i ka myalgia, ka ʻeha ma nā iwi, ma ka umauma).

Nā maʻi kūwaha: ≥1% - kōkuhi.

Nā ʻili: ≥1% - ʻeha ma ka ʻōpū o ka ʻōpū, ke ʻano maʻi o ka urinary.

Hoʻohui

Diuretics a me nā lāʻau antihypertensive. Hoʻokomo pū ʻo Thiazide diuretics i ka hopena. Ma mua o ka mālama ʻana me ka diuretics ma nā wai kiʻekiʻe e hiki ke alakaʻi i ka dehydration a hoʻonui i ka hōʻeha o ka hypotension arterial i ka hoʻomaka ʻana o ka mālama ʻana me ka irbesartan. Ua hui pū ʻia ʻo Irbesartan me nā lāʻau lapaʻau antihypertensive ʻokoʻa (beta-blockers, blockers kalima pālua).

Hoʻohui a me nā diuretics pākoleka. Hoʻonui i ka hopena o ka hyperkalemia i ka wā i hoʻohana pū ʻia me ka diuretics pākeleka me ka hoʻomākaukau ʻana i ka paʻakai.

Lithium: ka mea i hoʻonui ʻia i ka hoʻoliʻi ʻana o ka lumium serum a i ʻole ka hoʻonaninani ʻia me ka hoʻohana pinepine ʻana o ka lithium me ka angiotensin e hoʻohuli ana i ka inhibitor enzyme. E pili ana i ka irbesartan, he like ʻole ka hopena like ʻole i kēia lā, akā e nānā pono ʻia ka mālama ʻana i nā pae o ka serum lithium i ka wā e hoʻohana like ai i nā lāʻau.

Nā NSAID: me ka hoʻomohala ʻana o nā ʻāuna antagonis angiotensin II a me nā NSAIDs (no ka laʻana, he poʻe koho pumehana COX-2, acetylsalicylic acid> 3 g / lā a me nā NSAID e koho ʻole), hiki i kahi hopena hypotensive e nawaliwali.

E like me ka ACE inhibitors, ka hoʻohui pū ʻana o ka antagonist angiotensin II a me nā NSAID e hoʻonui i ka hōʻeha o ka hana renal impaired, a me ka hopena o ka hiki ʻole o ka pale renal, a me ka hoʻonui ʻana i nā pae pākahi serum, inā paha i nā mea maʻi me ka hana ʻoliʻoli paʻa. Me ka hoʻopuka ʻana o kēia hoʻohui, pono e mālama pono i nā mea maʻi. Pono ka poʻe maʻi e hana i ka hydration kūpono a nānā i ka hana o ka hana i ka wā o ka hui hoʻohui ʻana a me ka manawa ma hope o kona kū ʻana.

ʻO ka hole waiwai. ʻAʻole loli ia nā pharmacokinetics o irbesartan i ka wā i hui pūʻia me ka hydrochlorothiazide.

Ka hana nui ʻia o Irbesartan me ke komo ʻana o CYP2C9 a, i kahi mea haʻahaʻa, glucuronidation. ʻAʻole i ʻike nui ʻia i ke kipa pharmacokinetic a i ʻole me ke ʻano lāʻau lapaʻau me ka hui pū ʻana o irbesartan me warfarin, kahi lāʻau lapaʻau e hoʻākoakoa e CYP2C9. ʻAʻole i loiloi ʻia nā hopena o nā hōʻeuʻeu CYP2C9 e like me rifampicin ma pharmacokinetics o irbesartan.

ʻAʻole i loli ʻo Irbesartan i ka pharmacokinetics o digoxin.

Nahelehele Irbesartan

Hoʻohana ʻia me ka mālama pono i nā poʻe maʻi me ka hyponatremia (e mālama ai me ka diuretics, ke kaupalena ʻana i ka paʻakai o ka paʻakai me ka meaʻai, ka ʻōpala, ka luaʻi), i nā maʻi nā maʻi e pili ana i ka hemodialysis (hiki i ka hoʻomohala ʻana o ka maʻi hypaticension), a me nā mea maʻi maʻi. Pono e mālama ʻia i ka poʻe maʻi me ka hypovension renovascular ma muli o ka bilateral renal artery stenosis a i ʻole ke kaulua o ka ʻōpū o ke keiki hoʻokahi (ʻoi ka nui o ke ʻano o ka hypotension nui a me ka hana ʻole), aortic a mitral stenosis, obstructive hypertrophic cardiomyopathy, hōʻeha puʻuwai ʻōpū (hana III - IV papa. NYHA) a me ka maʻi puʻuwai coronary (piʻi i ka nui o ka hala o ka myocardial infarction, angina pectoris). E pale aku i ke kua o ka hana renal impaired, ʻike ʻia ka nānā ʻana o ka paʻakai serum a me nā pae creatinine. ʻAʻole ia no kau i nā poʻe maʻi me ka hyperaldosteronism maʻamau, me kahi pōkole koʻikoʻi (ʻaʻohe kumu kūleʻa), i nā mea maʻi me nā maʻi o ka maʻi hou (ʻaʻohe ʻike no ke kauka).

E hoʻokuʻu i ke ʻano a me ka ʻano

ʻO ke ʻano dosage o Irbesartan he mau uhi palaka film: biconvex, puni, ka ʻū a me ke kumu a he keʻokeʻo a keʻokeʻo paha (i loko o nā pūʻulu blister o 3, 4, 7, 10, 14, 15, 20, 25 a 30 mau pcs., I loko o kahi pahu pepa. Ua waiho ʻia he mau lā 1 he 10 a 10 paha i loko o nā kēke o ka polyethylene terephthalate 10, 14, 20, 28, 30, 40, 50, 60 a 100 mau pcs i loko o kahi pahu pahu, 1 hiki ke kau ʻia).

Aia ka hoʻonohonoho ʻana o ka papa pākuhi 1:

• mea waiwai: irbesartan - 75, 150 a 300 mg,
• Nā kumuhana hou (75/150/300 mg): cellulose microcrystalline - 24/48/96 mg, mole lactose (pākuʻu waiu) - 46.6 / 93.2 / 186.4 mg, colloidal silicon dioxide - 0.8 / 1 , 6 / 3.2 mg, sodium croscarmellose - 7.2 / 14.4 / 28.8 mg, magnesium stearate - 1.6 / 3.2 / 6.4 mg, povidone-K25 - 4.8 / 9, 6 / 19.2 mg
• shell (75/150/300 mg): titanium dioxide - 1.2 / 2.4 / 4.8 mg, macrogol-4000 - 0.6 / 1.2 / 2.4 mg, hypromellose - 2.2 / 4 4 / 8.8 mg.

Lapaʻau lāʻau

ʻO Irbesartan, ka mea nāna e koho i ka ʻōpū o ka ʻāuna o ka angiotensin II (type AT1), e kōkua ana i ka hoʻopau ʻana i ka hopena vasoconstrictor o ka angiotensin II, hoʻohaʻahaʻa i ka plasma o ke aldosterone i loko o ke koko (me ka pani ʻole o ka kinase II, ka mea e hoʻopau ai i ka bradykinin), e hōʻemi ana i ka pale aku o ka vaskoconstrictor o ke kaomiensin II. , ma hope o ke kahe a me ke kaomi i ke kaomi pulmonary. ʻAʻole pili ia i ka plasma plasma o ka cholesterol, triglycerides, glucose, uric acid a me ka hoʻōla ʻana o ka uric acid.

ʻO ka emi loa o ke kahe koko ke loaʻa ma hope o nā hola 3-6 ma hope o ka lawelawe waha o ka lāʻau, mālama ka hopena antihypertensive ma kahi o 24 mau hola. I kahi lā ma hope o ka hoʻokele ʻana, ʻo ka emi ʻana o ke kahe o ke koko he 60-70% i hoʻohālikelike ʻia me ka hoʻohaʻahaʻa loa ʻana i ka pakanā diastolic / systolic i ka pane ʻana i ka lawe i ka lāʻau. Ke lawe nei i kahi 150-300 mg 1 mau manawa i kēlā me kēia lā, ka nui o ke kahe o ke koko i ka hopena o ka manawa interdose (i.e., 24 mau hola ma hope o ka lawe ʻana i ka lāʻau lapaʻau) ma kahi e noho ana a moe paha i ka noho ʻana o ka mea maʻi ma ka awelika 5-8 / 8-13 mm Hg. ʻAniā. (kēlā) ʻoi aku ma mua o ka placebo. ʻO ka pane antihypertensive mai ka lawe ʻana i ka lāʻau lapaʻau ma kahi mahele o 150 mg 1 mau lā i kēlā me kēia lā ʻaʻole ʻokoʻa i ka hoʻohana ʻia ʻana o kēia ʻano maʻi i nā maʻi he 2. Hoʻomohala ka hopena antihypertensive o ka wahine a abbesartan i loko o 1-2 mau pule, a ua loaʻa ka hopena therapeutic kiʻekiʻe loa ma hope o 4-6 mau wiki mai ka hoʻomaka ʻana o ka mālama ʻana. Ma hope o ka pani ʻana i ka lāʻau lapaʻau, hoʻihoʻi ka maʻi koko i kona waiwai mua, me ka ʻole o ka hoʻomohala ʻana i kahi maʻi hoʻomaha. No ka hoʻokō ʻana i ka hopena antihypertensive paʻa, pono ʻia ka lawelawe lōʻihi.

ʻAʻole paʻa nā mea kūpono o ka irbesartan e pili ana i ka wahine a me ka makahiki.

ʻO nā mea maʻi o ka lāhui Negroid e pane iki ana i ka monotherapy me ka lāʻau lapaʻau.

Lapaʻau lāʻau

Hoʻopili: Irbesartan ma hope o ke kaʻina waha i lawe maikaʻi ʻia mai ka gastrointestinal tract. ʻO ka pae kiʻekiʻe o ka plasma nui i loko o ke koko a hōʻea ma hope o ka 1.5-2 mau hola ma hope o ka lawelawe waha, ka hōʻailona kūlohelohe kūloko he 60-80%. ʻAʻole pili ka ʻai i ka bioavailability. Loaʻa iā Irbesartan ka proportional dosis a me ka linear pharmacokinetics ma ka laulā o nā waihona o 10-600 mg, ma nā hapaha kiʻekiʻe (2 mau manawa kiʻekiʻe ma mua o ke ʻano i ʻōlelo ʻia), ʻo nā kinetics o ka mea e lilo ka huina.

ʻO ka hoʻohālikelike: ka paʻa ʻana o kahi mea i nā protein plasma e like me 96%. Hoʻopili ʻole ka pili ʻana me nā māhele ulu o ke koko. ʻO ka nui o ka hoʻoilina he 53–93 lita. ʻO ka ʻoi ʻana o ka pīpī me ke kōpana o kēlā me kēia lā i kahi 1 manawa i ka lā a hiki i ka lā 3 lā. Me nā ʻōmole kau pinepine, pau ka hōʻiliʻili ʻana o ka waiwai i loko o ke koko koko (9 mau kuhi ma ke ʻano o ke keiki-Pugh),

E pili ana i nā maʻi (nā maʻi / nā kūlana i mua o ka mana o Irbesartan e makaʻala).

• hypventrophic pono e hoʻonani,
• stenosis mitral / aortic stenosis,
• hyponatremia,
• hypovolemia,
• ka uka ana i ka papaʻai a me ka loaʻa ʻana o ka paʻakai paʻakai,
• huʻi, hoʻopuka
• bilateral renal stenosis,
• stenosis unilateral hoʻokahi o ka lāʻau o ka āiwi kūwaho,
• maʻi puʻuwai coronary a / a i ʻole nā ​​loiloi atherosclerotic o nā moku o ka uʻi,
• ka hana pohihihi o ka ulu ʻana o ka papa hana a III - IV e like me ka papa ʻo NYHA,
• nā mālamalama maikaʻi ʻole
• hyperkalemia
• kūlana ma hope o ke hili ʻana,
• hemodialysis
• hyperaldosteron's,
• hui pū me nā diuretics,
• ua hui pū ʻia me nā lāʻau anti-inflammatory non-steroidal, me ka inhibitor cyclooxygenase II, angiotensin-hoʻohuli i ka hoʻoneʻe a i ʻole o aliskiren,
• makahiki ma luna o 75 makahiki.

Nā ʻōkuhi no ka hoʻohana ʻana iā Irbesartan: ka ʻaea a me ka helu ʻana

Lawe ʻia ʻo Irbesartan ma ka ʻōlelo maʻamau, ke kīnā nei i nā papa āpau a me ka wai inu. Hiki iā ʻoe ke hoʻohana i ka lāʻau lapaʻau me ka ʻole o ka manawa o ka pāʻina.

ʻO ka dosis mua / mālama mua loa he 150 mg hoʻokahi i ka lā (e hāʻawi i ke kaomi o ke kahe koko i ke ao, i kekahi mau, aʻoi aku paha i nā mea maʻi ma ka hemodialysis, a i nā mea maʻi i ʻoi aku ma mua o 75 mau makahiki, ʻo ka hopena mua loa ʻo 75 mg). Inā ʻaʻole i hoʻokō ʻia ka hopena therapeutic, hiki ke hoʻonui ʻia i loko o ka 2 manawa.

I nā hihia ʻaʻole lawa o ka hoʻemi ʻana o ke koko e like me ka monotherapy, diuretics a me nā mea hana antihypertensive hiki ke hoʻohui iā Irbesartan.

Me ka hypertension arterial a me ka type 2 diabetes mellitus, pono e hoʻomaka i ka lāʻau me ka 150 mg hoʻokahi i ka lā a me ka hoʻonui pinepine ʻana i 300 mg, ʻoi aku ka nui o ka ʻono ma mua o ka mālama ʻana o ka nephropathy.

Hoʻohui nūhou

Me ka hoʻohana pū ʻana o Irbesartan me kekahi mau mea lapaʻau / lāʻau, hiki i nā hopena aʻe ke piʻi aʻe:

• Nā lāʻau lapaʻau e pili ana i ka aliskiren: ua hoʻohui ʻia ka hui ʻana i nā mea maʻi me ka maʻi mellitus a i ʻole ka hōʻemi a me ka hōʻemi ʻia ʻana o ka maʻi nui ʻole, ma nā maʻi ʻē aʻe ʻaʻole i kauoha ʻia.
• ka hoʻohuli ʻana o ka angiotensin i ka inhibitor enzyme: ua hoʻohui ʻia ka hui ʻana i nā mea maʻi me ka nephropathy maʻi, i nā maʻi ʻē aʻe ʻaʻole ia i ʻāpono ʻia,
• diuretics (ma mua o nā ʻaina kiʻekiʻe): puʻai a hoʻonui i ka hopena o ka hypotension arterial i ka hoʻomaka ʻana o ka hoʻohana ʻana o Irbesartan,
• diuretics a me nā mea antihypertensive hou: hoʻonui i ka hopena antihypertensive ((ʻo ke ʻano hui pū ʻana me ka ʻaole blocking β-adrenergic, lōʻihi ka lōkōlani kalepona saluran blockers a me nā thiazide diuretics),
• lithium mākaukau: ka hana hoʻi e hoʻihoʻi i ka serum lithium i loko o ke koko a i ʻole nā ​​mea momona (inā pono, ʻo ka hui pū ʻana e pono ai ka mālama ʻana i ka lithium concentration).
• Hoʻomapa pākaukau, nā hoʻonā waiololi aila i loaʻa ka potassium, ka diuretise potassium-sparing, nā lāʻau lapaʻau e hiki ke hoʻonui i ka momona o ka pāima i loko o ke koko, me ka heparin: he hoʻonui i ka paʻakai sima i loko o ke koko,
• nā lāʻau anti-inflammatory nonsteroidal: nāwaliwali i ka hopena antihypertensive o ka ʻōpala o ka neokarartan, me ka hoʻonui ʻana i ka hopena o ka hoʻomohala ʻana i nā hana maʻi o nā pēpē, me ka hopena o ka hiki ʻana o ka maʻi renal, a me ka hoʻonui ʻana i ka paʻakai serum, inā paha me ka hana renal i mua i ka hopena (e koi aku ana ka hui ʻana i ka akahele, ʻoiai ma ka poʻe maʻi a me ka hypovolemia , pono ʻoe e hoʻihoʻi i ka nui o ke kahe koko i ka wā holoʻokoʻa o ka hoʻohui pū ʻana, me ia hoʻi kekahi manawa ma hope o ia Pau i kekahi, kanaka hoʻoponoponoʻaʻa puʻuwai kuleana pili i).

Nā kikowaena o Irbesartan nā: Aprovel, Firmasta, Ibertan, Irsar, etc.

Nā Hōʻike ʻokoʻa ma Irbesartan

Wahi a nā loiloi, ʻo Irbesartan kekahi o nā lāʻau i loaʻa no ka mālama lōʻihi ʻana o ka maʻi hypertension maʻalahi / maʻalahi. Kahi ʻia kona kūpono i ka hypertension koʻikoʻi (me kahi lā o 300 mau lā) a me ka hoʻonui ʻana o ke kahe koko i ka pō ua ʻike pū ʻia. ʻO ka lāʻau lapaʻau, ma ke ʻano he lula, ua hoʻomanawanui maikaʻi ʻia a alakaʻi i ke kūkulu ʻana o ka hopena o ka hopena (ʻoiai nui ma ka ʻano o nā nāwaliwali a me ka huha) wale nō i nā kūlana kaʻina.

Aia nā hoʻokele kekahi i ka pono o Irbesartan e kū'ē i ka maʻi diabetes a me ka nephropathy maʻi.

Nā Hoʻohui

• makahiki i 18 makahiki
• haaheo
• hapai,
• hana waiū.

Ma ka akahele me ka hoʻomanaʻo ʻana he stenosis aortic valve, CHF, huehue, nā niniautuka hyponatremia, stenosisrenal hāmeʻa (unilateral and bilateral).

Irbesartan, nā ʻōlelo e pili ana i ka hoʻohana ʻana (Ke ʻano a me ke ʻano)

Lawe ʻia nā papa ma luna o kahi ʻōpū ʻole a i ʻole me ka meaʻai, hoʻopau ʻia. Hoʻomaka ka mālama ʻana me 150 mg i kēlā me kēia lā. Hāʻawi kēia helu i ka mana hoʻomohala i ka lā a hoʻohālikelike ʻia me 75 mg / lā.

Ma hope iho, hoʻonui lākou i 300 mg i kēlā me kēia lā, akā ʻaʻohe mea hou, no ka mea, he hoʻonui hou aʻe ʻaʻole ia i ka piʻi i ka hopena hypotensive. I kēia hihia, ʻoi ʻia e hoʻohui i nā diuretics. I nā poʻe maʻi ma mua o 75 mau makahiki, ma kēlā hemodialysis a me huehue hoʻomaka i ka mālama ʻana me 75 mg, ma ke ʻano like haehae maʻi. ^ E Ha yM. I nā maʻi me nā mālamalama maikaʻi ʻole pono e kaohi i ka ʻike mea hana a kāpili i ke koko. I ka ʻoi loa CH hoʻonui mahuahua azotemia a oliguriama huomania - kūlohelohe myocardial infarction. ^ E Ha yM. Hāʻawi ʻia ke mālama ʻia āhāhuʻe a me ka luhi, e hoʻohana i ka akahele ʻana i ka wā e holo kaʻa.

Ke keu

Hōʻike tachycardia a i ʻole bradociahoʻemi he pili koko, hāneʻe. ^ E Ha yM. Hoʻomaka ka mālamaʻana i ka lavage gastric a me ke kuhikuhi. carbon hoʻoneʻe. ^ E Ha yM. ʻO ka ʻōlelo aʻe, kahi mālama maʻi manamana.

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

Kuhi ʻia kēia lāʻau lāʻau i ke ʻano o nā papa pani. ʻO ka mea hana nui o ka lāʻau lapaʻau ka irbesartan ponoʻī iho. No kēia lāʻau lapaʻau i nā lāʻau antihypertensive. He ʻokoʻa loa ʻo Irbesartan. I loko o nā hale kūʻai, no ka mea kūʻai, hiki ke kūʻai ʻia no 260-300 p. (28 papa).

Nā hōʻailona a me nā contraindications no ke hoʻohana

Nā ʻatikala o Irbesartan, nā ʻōlelo no ka hoʻohana ʻana o ia mea e kamaʻilio ʻia ma lalo nei, e kuhikuhi ʻia ma kahi o kēia lāʻau lapaʻau i ka hihia ʻole i ka mea maʻi o kāna mau ʻāpana a me ka hemahema o ka loaʻa ʻana ma muli o ka nele o ka lāʻau lapaʻau. Eia hou ma ka ʻatikala e kamaʻilio mākou e pili ana i nā pono pili o kēia pono hana. Ma kēia e hoʻomaopopo mākou i ke ʻano o kēia lāʻau lapaʻau, a pehea pehea e lawe pono ai.

Ua kuhikuhi ʻia kēia lāʻau lapaʻau no ka hypertension primer. ʻO kekahi manawa i kuhikuhi ʻia no ka lua. Eia kekahi, hiki i ka lāʻau lapaʻau ke hoʻopilikia kino i ke kino o nā mea maʻi me ka maʻi e like me ka nephropathy me ka maʻi type 2 a me ke hypertension. Eia naʻe, i kēia hihia, ua hoʻohana ʻia ka lāʻau lapaʻau "Irbesartan" me nā hui pū kekahi.

ʻAʻohe ʻano contraindications kūikawā no kēia lāʻau lapaʻau. ʻAʻole hiki iā ʻoe ke lawe wale i kēlā poʻe i kūpaʻa i kekahi o kāna mau ʻāpana. Eia nō hoʻi, ʻaʻole ʻae ʻia ka hoʻohana ʻana i kēia lāʻau lapaʻau no nā wahine hāpai a hānai hānai, nā keiki ma lalo o 18 makahiki o kona mau makahiki. I kekahi mau hihia, pono e mālama ʻia kēia lāʻau i ka mālama. Ma lalo o ka mākaʻi lapaʻau paʻa, inu lākou ia mea, no ka laʻana, i nā maʻi e like me ka hyponatremia a me ka hoʻomōhū.

Hiki ke loaʻa nā hopena hopena

ʻO ka hoʻohana ʻana o "Irbesartan" hiki wale nō ke kuhikuhi ʻia e ke kauka. I loko o nā haleʻai, kūʻai aku kēia mea hana ma ka lāʻau lapaʻau. Hiki i nā hopena ʻokoʻa Irbesartan ke hāʻawi i nā ʻano ʻokoʻa like. ʻO kahi laʻana, hiki i kekahi mea maʻi ke loaʻa i nā pilikia aʻe:

hōʻeha a ʻeha paha,

ʻōpū o ke ea, ʻohi ʻia me ke kuni,

ka ʻeha, ʻehaʻā, ke lua a me ka luaʻi,

ʻO kekahi manawa hāʻawi kēia lāʻau lapaʻau i ka hopena maikaʻi ʻole e like me ka maʻi urinary a i ʻole ka ʻeha ʻeha.

Pehea e hana ai ka lāʻau lapaʻau?

ʻO ka lāʻau Irbesartan mai ke kaʻe o ka digestive kahi e hoʻoulu maikaʻi a maikaʻi. ʻO kāna hana ikaika e hōʻea i kona kaila nui loa i ka plasma koko ma hope o nā hola 1.5-2 ma hope o ka hoʻokele ʻana. I ke kino o ka mea maʻi, ua hoʻopaʻa ʻia kēia lāʻau lapaʻau i ka mea hoʻokele o ka AT1, e hōʻemi ana i nā hopena ola e pili ana i ka agiotensin II, e hoʻoulu i ka hoʻokuʻu i ka ald testosterone a hoʻōla i ka ʻōnaehana o ka simpathetic. Ma muli o kēia mau mea a pau, loaʻa ka mea maʻi i ka hopena o ke koko.

Hoʻokuʻu ʻia kēia lāʻau lāʻau mai ke kino o ka mea maʻi me ka urine a me ka bile.

ʻO nā meaʻala maikaʻi loa o Irbesartan

Inā loaʻa nā contraindications no ka lawe ʻana i kēia mau peni a i kekahi kumu ʻē aʻe paha, e kuhikuhi paha ke kauka i nā mea i koho ʻia no ka mea maʻi. ʻO ka pinepine, ʻo nā lāʻau lapaʻau me ka hopena e like me ke ʻano like, e like me Aprovel, Valzan, Losartal, a i ʻole Irsar, e hoʻohana ʻia no ka mālama maʻi.

Ua loaʻa kēia mau kikoʻī āpau o Ibersartan i nā loiloi maikaʻi loa mai nā maʻi a me nā kauka.

ʻO ka lāʻau lapaʻau Aprovel: hoʻokuʻu i nā puka a me nā hōʻike

ʻO ka mea hana nui i kēia lāʻau lapaʻau ʻo irbesartan. ʻO ia, ʻo ia, ke pili nei i ke ʻano like o nā ʻano i wehewehe ʻia e mākou. Nā hōʻailona no ka hoʻohana ʻana me kēia lāʻau lapaʻau e like me ka Irbesartan. E hoʻohana nui iā ia no ka hypertension maʻamau a me ka nephropathy i hui pū me nā mea'ē aʻe. Hoʻopili ʻia kona mau ʻaoʻao ʻaoʻao e like me kēlā me ka Irbesartan. Ua kau ʻia kēia lāʻau lapaʻau i nā ʻano like like.

Nui nā helu kikoʻī o Irbesartan loiloi i kūpono no ka maikaʻi. Akā ʻo ka manaʻo maikaʻi loa ma waena o nā mea maʻi a me nā kauka e pili ana i ka mea pono o Aprovel. Ua ʻoi aku ka uku o kēia lāʻau lapaʻau ma mua o Irbesartan. No nā papa 28 o kēia pono hana e uku iā 550-650 p. Eia naʻe, ʻo ka lāʻau lapaʻau e hana ʻia e ka hui kaulana ʻo Sanofi-Winthrop. ʻO ia hoʻi, he mea koho maikaʻi inoa inoa no Irbesartan.

ʻO ka hua'ōlelo "Irsar"

Kuhi pinepine nā kauka i kēia analogue no ka hypertension koʻikoʻi pinepine. ʻO ka hana ikaika ma ia mea he irbesartan. Kuhi ʻia kēia lāʻau lāʻau i ke ʻano o nā papa maʻamau me ka pilikia. ʻO nā maʻi, nā contraindications a me nā ʻōlelo aʻoaʻo no ka hoʻohana ʻana me ia ʻaʻole ʻokoʻa ʻole iā Irbesartan. Pono kēia lāʻau lapaʻau ma kahi o 350-450 p. no 28 papa. Akā i kekahi manawa i loko o nā lāʻau lapaʻau e hāʻawi pū ʻia no 600-650 r.

ʻO ka lāʻau lapaʻau "Valzan"

ʻO nā mea i hoʻohālikelike ʻia ai nā Irbesartan i hōʻike ʻia ma luna nei e pili ana i ka lako hana like. Akā ua hoʻololi kēia lāʻau i ka hoʻolālā like ʻole. ʻO nā mea nui e hana ai i ka lāʻau lapaʻau "Valzan", no ka laʻana, ʻo ka hydrochlorothiazite a me valsartan. Hāʻawi ʻia kēia lāʻau lapaʻau i ka mākeke ma ke ʻano o nā papa i hala. Ma kahi o Irbesartan, hiki ke kuhikuhi ʻia no ka hypertension arterial. Eia nō kekahi, nā hōʻailona no ka hoʻohana ʻana i kēia lāʻau lapaʻau ka hōʻeha ʻana o ka naʻau a me ka pohō o ka naʻau puʻukū.

ʻAʻole hiki iā ʻoe ke lawe iā "Valzan" no nā maʻi ʻeha koʻikoʻi, ka hapai, ʻo ka wā hoʻi ka umauma. Eia nō hoʻi, ʻaʻole i kuhikuhi ʻia kēia kaila no nā keiki ma lalo o ka makahiki 18. Hiki i nā mea kūpono o kēia lāʻau lapaʻau ke hāʻawi like i ka like me Irbesartan. He paleke nā lāʻau lapaʻau "Valzan". No 30 mau papa o kēia huahana i kahi lāʻau lapaʻau e pono ai ʻoe e uku e pili ana i ka 15-20 p.

ʻO ka lāʻau mua o kēia lāʻau lapaʻau ka 80 mg hoʻokahi i ka lā. I nā mau hebedoma hebedoma e hiki mai ana e hoʻonui iā 160 mg i kēlā me kēia lā. I nā hihia koʻikoʻi, hiki i ka mea maʻi ke lawe i ka 320 mg i kēlā me kēia lā.

ʻĀpana "Losartan"

Hiki ke kūʻai lilo ʻia kekahi mau analogues o Irbesartan ma Lūkini. ʻAʻole pili kēia i ka lāʻau lapaʻau Valzan wale nō, akā naʻe, no ka laʻana, ka lāʻau lapaʻau Lozartan. He mea maikaʻi loa iā Irbesartan. ʻO ke kumu nui o kēia lāʻau lapaʻau ka losartan potassium. Hoʻohui ʻia ka lāʻau i nā papa kuʻina. "Losartan" hiki ke kahakaha ʻia i nā mea maʻi me ka hypertension arterial, ka puʻuwai naʻau, a ma nā maʻi ʻē aʻe.

He nui hou aku nā lāʻau lapaʻau ma mua o nā lāʻau i hōʻike ʻia ma luna. I ka hoʻohuiʻana i ka wā hāpai a me ka wā kamaliʻi, ʻaʻole pono ka inu ʻana o kēia lāʻau lapaʻau, no ka laʻana, me ka dehydration, pilikia nui ʻole o ka renal, i ka manawa like o Aliskiren. Mālama kēia lāʻau lapaʻau e pili ana i 60-100 rubles ma ka mākeke no kahi pā o 30 mau papa.

ʻO ka manaʻo o nā poʻe maʻi e pili ana i ka lāʻau lapaʻau "Irbesartan"

No laila, ua kuhi mākou i ka mea e hoʻomākaukau pono ai ka Irbesartan (nā ʻōlelo no ka hoʻohana ʻana, nā analogues). ʻO nā loiloi e pili ana i kēia lāʻau lapaʻau ka mea kūpono loa wale nō. Ke hoʻoikaika maikaʻi nei ka lāʻau lapaʻau. Eia nō naʻe, ʻo ka lawe ʻana ia e loaʻa i ka hopena maikaʻi loa, e like me ka nui o nā mea maʻi, he lōʻihi lōʻihi.

Pākuʻi helu

ʻO nā papa ʻoniʻoni kiʻi 75 mg, 150 mg a 300 mg paha

Aia ma ka papa papa

mea waiwai irbesartan - 75 mg a i ole 150 mg, a i 300 mg

i lokokōkuas emea hoʻonaʻauaoaka, aka: microcrystalline cellulose PH 101, calcium carmellose, povidone K-30, silicon dioxide colloidal anhydrous, calcium stearate, wai maʻemaʻe.

ʻili kūpeʻe: Opadry keʻokeʻo OY-S-38956, wai maʻemaʻe

opio hui keʻokeʻo OY-S-38956: hypromellose, titanium dioxide E171, talc.

ʻO nā papa kālai Capsule, me kahi papa biconvex, i kāwili ʻia me ka kiʻi ʻoniʻoni o ke keʻokeʻo a i ʻole like ʻole hoʻi ke keʻokeʻo me ke kālai ʻia "158" ma ka lima hoʻokahi a me ka "H" ma ka ʻaoʻao (no kahi pāʻālua o 75 mg).

ʻO nā papa kālai Capsule, me kahi papa biconvex, i kālai ʻia me ka kiʻi ʻoniʻoni o ke keʻokeʻo a i ʻole ʻoniʻoni paha keʻokeʻo me ke kālai ʻia "159" ma ka ʻaoʻao hoʻokahi a me "H" ma ka ʻaoʻao ʻē aʻe (no kahi dute 150 mg).

ʻO nā papa kālai Capsule, me kahi papa biconvex, i kāwili ʻia me ka kiʻi ʻoniʻoni o ke keʻokeʻo a i ʻole like ʻole hoʻi ke keʻokeʻo me ke kālai ʻana "160" ma ka ʻaoʻao a me ka "H" ma ka ʻaoʻao (ma kahi ʻano he 300 mg).

Phui kūpeʻa

ʻO nā hopena hōʻeha e pili ana i ka ʻōnaehana renin-angiotensin. Nā antagonist Angiotensin II. Irbesartan

ATX Code C09CA04